0O8G Stock Chart & Stats
€3.02
€0.00(0.00%)
At close: 4:00 PM EDT
€3.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.02 - €3.02
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€16.52M
Enterprise Value€107.73M
Total Cash (Recent Filing)€19.21M
Total Debt (Recent Filing)€105.85M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding95,417,380
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.67Price Target Upside-77.85% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.45
Revenue Forecast (FY)€98.94M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling And Gross MarginThe substantial multi-year revenue increase shows that MDxHealth has expanded commercialization of its molecular testing portfolio. A gross margin near 60% also indicates meaningful economics per test, supporting reinvestment and potential operating leverage if growth continues.
Broadening Prostate Diagnostics PortfolioThe combination of tissue-based and liquid-based prostate tests gives MDxHealth multiple ways to serve urologists and clinical decisions. Rapid Exo mdx volume growth suggests the acquired franchise is gaining utilization and can diversify the company’s testing revenue base.
Clinical Evidence And Product DevelopmentPeer-reviewed evidence and continued clinical research can strengthen physician confidence in MDxHealth’s assays and support their role in care decisions. Ongoing AI initiatives may add functionality across urology and pathology customers, reinforcing the product platform over time.
Bears Say
Persistent Losses And Negative Cash FlowMDxHealth remains dependent on external funding because its operations are not yet self-financing. Persistent operating and net losses limit flexibility to invest in growth, while continued cash burn increases the importance of achieving sustainable profitability before liquidity is exhausted.
Balance-Sheet StrainThe sharp increase in debt alongside negative equity materially weakens financial resilience. This capital structure can constrain future investment and raise financing pressure, while any additional equity funding could be needed to support obligations and extend the company’s operating runway.
Sales Disruption And Guidance SuspensionSales-force turnover has disrupted execution at a time when the company needs sustained adoption growth across its diagnostic portfolio. The Q3 miss and suspended guidance reduce visibility into near-term revenue recovery and indicate that commercial integration remains an important operating risk.
MDxHealth News
0O8G FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest share price was €3.02 and its highest was €3.02 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is €16.52M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is Nov 12, 2026 which is in 19 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on Aug 13, 2026. The company reported -€0.16 earnings per share for the quarter, beating the consensus estimate of -€0.172 by €0.012.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Overvalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.08.
How many shares outstanding does MDxHealth have?
MDxHealth has 95,417,380 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -€0.16 in its last earnings report, beating expectations of -€0.172. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in GB:0O8G
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MDxHealth
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
0O8G Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of strong operational and strategic progress — significant sequential revenue acceleration, a successful customer transition, removal of a $10.4M contingent liability, clinical data momentum, and a $20M capital raise — alongside meaningful near-term financial challenges including wider operating and net losses, negative adjusted EBITDA, gross margin compression, and tissue volumes still down year-over-year. Management reiterated full-year revenue guidance ($110M–$115M) and a path to adjusted EBITDA positivity by year-end, striking an overall tone of cautious optimism while acknowledging current profitability headwinds.View all GB:0O8G earnings summaries0O8G Stock 12 Month Forecast
Average Price Target
€0.67
▼(-77.85% Downside)